Global Proteomic Determination of the Poly-Pharmacological Effects of PARP Inhibitors Following Treatment of High-Grade Serous Ovarian Cancer Cells.

Int J Mol Sci · 2025 · PMC12733200 · PMID 41465250

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

We observed a decreasing trend in NDUFS3 abundance following PARPi treatment; however, statistical significance was achieved only after Rucaparib treatment ( Figure 4 E).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.